BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 16723574)

  • 1. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
    Manavathu EK; Cutright JL; Chandrasekar PH
    Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.
    Cicogna CE; White MH; Bernard EM; Ishimura T; Sun M; Tong WP; Armstrong D
    Antimicrob Agents Chemother; 1997 Feb; 41(2):259-61. PubMed ID: 9021176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
    Rieg G; Spellberg B; Schwartz J; Fu Y; Edwards JE; Sheppard DC; Ibrahim AS
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2895-6. PubMed ID: 16870798
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis.
    Mouton JW; te Dorsthorst DT; Meis JF; Verweij PE
    Med Mycol; 2009 Dec; 47(8):802-7. PubMed ID: 19180360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
    Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
    Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
    Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.
    Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
    J Pharm Pharmacol; 2005 Oct; 57(10):1289-95. PubMed ID: 16259757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
    Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
    Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
    J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
    Clemons KV; Parmar R; Martinez M; Stevens DA
    J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model.
    Hachem R; Bahna P; Hanna H; Stephens LC; Raad I
    Antimicrob Agents Chemother; 2006 May; 50(5):1823-7. PubMed ID: 16641455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.